SynthesisJournal of neuro-oncology2025
Extent of resection and adjuvant treatment in adult cerebellar glioblastoma: systematic review and meta-analysis of survival outcomes.
Synthesis in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on: "Extent of resection and adjuvant treatment in adult cerebellar glioblastoma: systematic review and meta-analysis of survival outcomes".Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCerebellar glioblastoma (cGBM) is a rare subtype, comprising of < 1% of patients with GBMs. This study sought to identify predictors of survival for patients with cGBM through an individual patient data (IPD) meta-analysis, focusing on the impact of chemoradiotherapy (CRT) and extent of resection (EOR).
methodsFollowing PRISMA-IPD guidelines, we conducted a systematic review and Individual Patient Data (IPD) meta-analysis of 13 retrospective studies (113 adults) with IDH-wildtype cerebellar glioblastoma. Variables included demographics, tumor location, KPS, MGMT, TP53, extent of resection (GTR, STR, PR, biopsy), and CRT. Kaplan-Meier estimated OS and PFS; unadjusted and adjusted Cox models assessed predictors. Hazard ratios for CRT vs. monotherapy and GTR vs. incomplete resection were pooled in a two-stage random-effects model (Hartung-Knapp). Analyses used R (v4.4.2) and JMP Pro 17.
resultsMean age was 54.9 years; 64% were male. GTR was performed in 37%, PR in 43%, STR in 11%, and biopsy in 10%. CRT was associated with improved OS (18 vs. 7 months; p = 0.02) and PFS (12 vs. 2.5 months; p = 0.0205) compared to monotherapy on Kaplan-Meier analysis. Two-stage IPD meta-analysis showed a 72% reduced risk of death with CRT (HR 0.28; 95% CI: 0.15-0.51; p = 0.0119), with similar significance in one-stage unadjusted Cox models (HR 0.49; 95% CI: 0.26-0.91; p = 0.0233). EOR comparisons were non-significant in meta-analyses, though GTR vs. biopsy showed early separation on Wilcoxon testing (p = 0.0422).
conclusionIn this pooled IPD meta-analysis of cGBM, the use of CRT remained the only consistent and independent predictor of improved survival. GTR conferred a survival advantage over biopsy, likely reflecting the clinical benefit of debulking, however its advantage over subtotal resection was not statistically significant. These findings reinforce CRT as the maintstay of treatment highlighting the need for individualized strategies in cGBM. In selected cGBM patients, gross total surgical resection and adjuvant chemo-RT result in overall survival outcomes comparable with supratentorial GBM. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
41460384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.